Company news: Merck, Millennium, Novo Nordisk and Genentech

Share this article:

Merck can update its Vytorin label with data suggesting a cardiovascular benefit in patients with kidney disease, the drugmaker said, but may not claim a new indication. That was the FDA's decision, despite a unanimous vote by an advisory panel in favor of the pre-dialysis outcome. The vote had followed release of data from the SHARP trial, in which Vytorin (ezetimibe/simvastatin) reduced major vascular events in patients with moderate-to-severe chronic kidney disease (CKD). The FDA permitted no such label update for Vytorin's LDL-lowering cousin, Zetia (ezetimibe).

Biotechs made a showing in Fortune Magazine's list of 100 Best Companies to Work For, starting with Millennium: The Takeda Oncology Company, which placed at 35 and was followed closely by Novo Nordisk at 43. Genentech was No. 68.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.